BURLINGTON, Mass. — A new intravascular imaging system from Infraredx Inc. allows in vivo chemical analysis to help manage coronary artery disease. The Advanced TVC Imaging System combines near-infrared spectroscopy (NIRS) with intravascular ultrasound. The FDA-approved device is intended he help cardiologists predict the risk of peri-procedural heart attacks by assessing not only the degree of stenosis, but also the presence and extent of lipid-core plaques, which are known to complicate stenting procedures and suspected to cause most heart attacks. The company’s Extended Bandwidth ultrasound technology harmonizes multiple signal frequencies to produce an image of the complete vessel that allows for easy identification of the lumen, plaque and vessel structure. For more information, visit www.infraredx.com.